Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30253474 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| Bromide SCHEMBL8668237 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL25430987 | 0.95 | ALDH1A1 (0.62) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL18793809 | 0.90 | TSHR (0.75) | SMN1; SMN2NOTUMALDH1A1POLBTSHR | |
| SCHEMBL10422954 | 0.89 | TSHR (0.69) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL1545217 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL342522 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL14202790 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL25391399 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB | |
| SCHEMBL29520673 | 0.84 | NOTUM (0.69) | SMN1; SMN2NOTUMALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20150299225-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299225-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299225-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-8916550-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916550-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916550-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2392328-A1 | Compounds for modulating TRPV3 Function | Hydra Biosciences, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20100273777-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7803790-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803790-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803790-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2008060626-A9 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008060626-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20070213321-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213321-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213321-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20060270688-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270688-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | SMN1; SMN2 2219/4885NOTUM 3883/4885ALDH1A1 3074/4885 |
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | SMN1; SMN2 2219/4885NOTUM 3883/4885ALDH1A1 3074/4885 |
| US-20150299225-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | SMN1; SMN2 2219/4885NOTUM 3883/4885ALDH1A1 3074/4885 |
| US-20100273777-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | SMN1; SMN2 2219/4885NOTUM 3883/4885ALDH1A1 3074/4885 |
| US-20070213321-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | SMN1; SMN2 2219/4885NOTUM 3883/4885ALDH1A1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.